BUFFALO, NY -- (Marketwire) -- 04/21/10 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that Andrei Gudkov, Ph.D., D. Sci., the Company's Chief Scientific Officer and Senior Vice President of Basic Science at Roswell Park Cancer Institute, presented at the 101st American Association for Cancer Research (AACR) Annual Meeting, April 17-21, in Washington, DC.

Dr. Gudkov's presentation, "Targeting transcriptional regulators for simultaneous modulation of p53 and NF-kappaB in cancer treatment," was part of the Major Symposia on Unconventional Therapeutic Targets chaired by Lyubomir Vassilev of Hoffmann-La Roche, Inc., on April 19.

"This was the first disclosure to the cancer research community of the properties and novel mechanism of action of a major class of emerging anticancer compounds from the CBLI drug portfolio," stated Dr. Gudkov. "Curaxins are unique in their ability to simultaneously target several signal transduction pathways frequently deregulated in cancer. This property has made them effective in many experimental cancer models and encourages us as we seek to translate Curaxins into first-in-class multi-targeted anticancer agents."

In December, CBLI announced that it formally entered into a 50/50 joint venture, Incuron, with Bioprocess Capital Ventures, a Russian Federation venture capital fund, to develop the Company's Curaxin compounds for cancer applications.

Cleveland BioLabs is developing a pipeline of products for multiple defense and medical applications from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation and chemotherapy. Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer agents.

For more information about the AACR Annual Meeting, please refer to: http://www.aacr.org/home/scientists/meetings--workshops/aacr-101st-annual-meeting-2010.aspx

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2009.

Rachel Levine, Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com